BiotechTube
Var2 Pharmaceuticals

Var2 Pharmaceuticals

Copenhagen, Denmark· Est.
var2pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Var2 Pharmaceuticals is pioneering a novel oncology platform based on targeting oncofetal chondroitin sulfate (ofCS), a carbohydrate modification expressed in over 95% of cancers but absent in most healthy tissues. Its lead assets, called Vartumabs, are proprietary antibodies with high affinity for ofCS, being developed in multiple formats including antibody-drug conjugates (ADCs), bispecifics, and cell therapies. The company is clinical-stage, having initiated a Phase 0 imaging trial in late 2024 and planning a Phase I/IIA trial for its lead ADC candidate in 2027.

Oncology

Technology Platform

Proprietary monoclonal antibodies (Vartumabs) targeting oncofetal chondroitin sulfate (ofCS), a pan-cancer tumor-specific carbohydrate antigen. Platform enables development of Antibody-Drug Conjugates (ADCs), bispecifics, and cell therapies.

Opportunities

The pan-cancer expression of its target (ofCS) presents a massive addressable market across multiple solid and hematologic tumors.
The modular Vartumab platform allows for multiple shots on goal across ADC, bispecific, and cell therapy modalities, creating a potential pipeline-in-a-product.

Risk Factors

Major clinical development risk as therapeutic efficacy of targeting ofCS is unproven in humans.
The company is pre-revenue with a lengthy clinical timeline (Phase I/II trial in 2027), creating significant financing risk.
Complex carbohydrate-targeting presents potential manufacturing and biological unpredictability challenges.

Competitive Landscape

Var2 is first-in-class targeting oncofetal chondroitin sulfate (ofCS), with no direct competitors mentioned. However, it competes indirectly with all targeted oncology therapies, especially ADCs and bispecifics targeting other tumor antigens. Its key differentiator is the unique, pan-cancer carbohydrate target versus more common protein targets.

More companies in Biologics / Biosimilars →More companies in Denmark →